A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

NCT06090799 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of Graft Rejection After Organ Transplantation

Interventions

DRUG: SHR-3032
DRUG: SHR-3032 Placebo

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd